ClinicalTrials.gg
Active, not recruitingNCT04862663CAPItello-292Updated Aug 17, 2026

Capivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer (CAPItello-292)

A Phase 3 interventional study of Capivasertib and Fulvestrant in Locally Advanced (Inoperable) or Metastatic Breast Cancer, sponsored by AstraZeneca. Active, not recruiting at 225 sites in 23 countries. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2026-08-17.

Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
893
Allocation
Randomized
Ages
18 Years to 99 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 20 studies testing capivasertib in Breast Neoplasms — 3 open to participants now, 13 under way, 7 of them phase 3. capivasertib · Breast Neoplasms.

Enrollment
6th of 20
893 · median 247
Started
2021
with 1 other
Phase 3
7 of 20
2 open now
Primary completion
2027-11
later than 7 of 12 live
Registered
14th of 20
by date
Lead sponsor
8 of 20
AstraZeneca

Among the 20 studies testing capivasertib in Breast Neoplasms, this one is the 6th largest by enrollment, is one of 2 that started in 2021, is one of 7 in phase 3, reaches primary completion later than 7 of the 12 other live ones, and was the 14th registered.

Breast Neoplasms

14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

3 of the 20 studies testing capivasertib in Breast Neoplasms are open now, in 4 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About capivasertib

capivasertib: first FDA approval 2023 (TRUQAP), first EMA approval 2024. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.

This study: 18 Years to 99 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies testing capivasertib in Breast Neoplasms, or all of them as a file.
02

Study summary

A Phase Ib/III Open-label, Randomised Study of Capivasertib plus CDK4/6 Inhibitors and Fulvestrant versus CDK4/6 Inhibitors and Fulvestrant in Hormone Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative Locally Advanced, Unresectable or Metastatic Breast Cancer (CAPItello-292)

Read the detailed description

This Phase Ib/III study (CAPItello-292) aims to evaluate the efficacy, safety and the degree of added benefit of capivasertib combined with CDK4/6i and fulvestrant in participants with locally advanced (inoperable) or metastatic HR+/HER2- breast cancer. Although the dosing regimens of capivasertib + fulvestrant and of CDK4/6i + fulvestrant are established separately, the dose and schedule for the triplet combinations (capivasertib + CDK4/6i + fulvestrant) need to be confirmed. Therefore, the initial dose finding Phase Ib part of the study will determine the recommended Phase III doses (RP3D) of the triplet combinations. The Phase III part of the study will evaluate the efficacy, safety and the degree of added benefit of the triplet combinations of capivasertib and fulvestrant with investigator's choice of CDK4/6i (either palbociclib or ribociclib at safe and tolerable doses, once identified) in comparison with a control arm (fulvestrant + investigator's choice of CDK4/6i [palbociclib or ribociclib]) in a ER+ HER2- maC high risk population that did not receive prior endocrine therapy in the advanced setting.

03

Conditions studied

  • Locally Advanced (Inoperable) or Metastatic Breast Cancer

Browse trials for

Keywords

  • Locally advanced (inoperable) or Metastatic Breast Cancer
04

Who can participate

Ages eligible
18 Years to 99 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key inclusion criteria for both phases:

  1. Adult females (pre-/peri-/ and ), and adult males.
  2. confirmed HR+/ - breast cancer determined from the most recent tumour sample (primary or ) per the American Society of Clinical Oncology and College of American Pathologists guideline. To fulfil the requirement of HR+ disease, a breast cancer must express ER with or without co-expression of progesterone receptor.
  3. Eligible for fulvestrant therapy and at least one of the following: palbociclib, ribociclib, or abemaciclib, as per local investigator assessment. Previous tolerance to specific CDK4/6 inhibitors and dose levels required.
  4. Adequate organ and bone marrow functions.
  5. Consent to provide a mandatory FFPE tumour sample.

Key inclusion criteria only for phase III:

  1. Previous treatment with an ET (tamoxifen, AI, or oral SERD) as a single agent or in combination, with radiological evidence of breast cancer recurrence or progression while on, or within 12 months of, completing a (neo)adjuvant ET regimen.
  2. Provision of mandatory blood samples at screening for central testing using an ctDNA test to be stratified based on PIK3CA/AKT1/PTEN status.
  3. Be eligible for fulvestrant and at least one out of palbociclib or ribociclib (depending on the available CDK4/6i options at time of enrolment), as per local investigator assessment.
  4. Have (s) according to version 1.1 (RECIST v1.1) or, in the absence of measurable disease, lytic or mixed bone lesions that can be assessed by computed tomography (CT) or magnetic resonance imaging (MRI).

Key exclusion criteria for both phases:

  1. History of another primary except for malignancy treated with curative intent with no known active disease ≥ 2 years before the first dose of study intervention and of low potential risk for recurrence.
  2. Radiotherapy within 2 weeks prior to study treatment initiation.
  3. Major surgery or significant traumatic injury within 4 weeks of the first dose of study treatment.
  4. Persistent toxicities ( Grade >1) caused by previous anticancer therapy, excluding alopecia. Participants with irreversible toxicity that is not reasonably expected to be exacerbated by study intervention may be included (eg, hearing loss or peripheral sensory neuropathy) after consultation with the AstraZeneca study physician.
  5. Spinal cord compression, or unless these lesions are definitively treated (eg. radiotherapy, surgery) and clinically stable off for management of symptoms for at least 4 weeks prior to study treatment initiation.
  6. Any of the following cardiac criteria at screening:

    (a). Mean resting interval (QTcF): (i) Participants to be treated with palbociclib:: QTcF ≥ 470 ms obtained from the average of 3 consecutive (triplicate) ECGs (ii) Participants to be treated with ribociclib: QTcF ≥ 450 ms obtained from the average of 3 consecutive (triplicate) ECGs (iii) Participants to be treated with abemaciclib (Phase Ib only): QTcF ≥ 470 ms obtained from the average of 3 consecutive (triplicate) ECGs (b). Any abnormalities in cardiac rhythm, conduction or morphology of resting (eg, complete left bundle branch block, third-degree heart block) (c). Any factors that increase the risk of QTc prolongation or risk of arrhythmic events (d). Experience of any of the following procedures or conditions in the preceding 6 months: coronary artery bypass graft, angioplasty, vascular stent, myocardial infarction, unstable angina pectoris, congestive heart failure (NYHA) grade ≥ 2 (e). Uncontrolled hypotension (f) uncontrolled hypertension (g). Cardiac outside institutional range of normal or \< 50% (whichever is higher)

  7. uncontrolled or high grade or symptomatic arrhythmia and atrial fibrillation
  8. Any of these clinically significant abnormalities of glucose metabolism at screening:

    1. . diabetes mellitus type I or type II requiring insulin treatment
    2. . (HbA1c) ≥ 8.0% (63.9 mmol/mol)
  9. Previous bone marrow transplant or solid organ transplant.

Key exclusion criteria for the phase III only:

  1. Any prior treatment with, AKT, PI3K or mTOR inhibitors.
  2. Prior treatment with CDK4/6 inhibitors in the metastatic setting (prior CDK4/6 inhibitors permitted in the setting provided there was a CDK4/6i treatment free interval of at least 12 months).
  3. More than 1 for metastatic disease.
  4. Any line of endocrine-based therapy for inoperable locally advanced or metastatic disease.
Terms in these criteria, in plain language(21)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
893 participants (actual)

Study arms

  • Experimental
    Capivasertib Plus Palbociclib and Fulvestrant

    Capivasertib Plus Palbociclib and Fulvestrant (Ph 1b)

    Drug: Capivasertib · Drug: Fulvestrant · Drug: Palbociclib

  • Experimental
    Capivasertib Plus Ribociclib and Fulvestrant

    Capivasertib Plus Ribociclib and Fulvestrant (Ph 1b)

    Drug: Ribociclib

  • Experimental
    Capivasertib Plus Abemaciclib and Fulvestrant

    Capivasertib Plus Abemaciclib and Fulvestrant (Ph 1b)

    Drug: Abemaciclib

  • Experimental
    Capivasertib Plus Fulvestrant and Investigator's choice of CDK4/6i (palbociclib or ribociclib)

    Capivasertib Plus Fulvestrant and Investigator's choice of CDK4/6i (palbociclib or ribociclib) (Ph III)

    Drug: Capivasertib

  • Active comparator
    Fulvestrant and Investigator's choice of CDK4/6i (palbociclib or ribociclib)

    Fulvestrant and investigator's choice of CDK4/6i (palbociclib or ribociclib) (Ph III)

    Drug: Fulvestrant

Interventions

  • Phase Ib: Capivasertib 320 mg/ 400 mg administered PO BD 4 days on /3 days off per week for 4 weeks (28 days cycle) Phase III: : Capivasertib, administered PO BD 4 days on / 3 days off per week for 4 weeks (28 days cycle) at the dose confirmed in the phase Ib portion

  • Phase Ib and Phase III: 500 mg (2 injections of 250 mg) on Day 1 of Weeks 1 and 3 of Cycle 1, and then on Day 1, Week 1 of each cycle thereafter

  • Phase Ib: 100 mg/ 125 mg. Once daily for 21 consecutive days followed by 7 days off treatment to comprise a complete 28-day cycle Phase III: Administered once daily for 21 days of 28-day cycle, at the dose of 125 mg.

  • Phase Ib: 200 mg/ 400 mg/ 600 mg. Once daily for 21 consecutive days followed by 7 days off treatment to comprise a complete 28-day cycle Phase III: Administered once daily for 21 days of 28-day cycle, at the dose confirmed in the phase 1b portion.

  • Phase Ib: 50 mg/ 100 mg/ 150 mg. Twice daily for 28 consecutive days to comprise a complete 28-day cycle

06

What researchers measure

Primary outcomes

  1. Phase Ib: 1. The number of participants with dose-limiting toxicity, as defined in the protocol.

    Dose-limiting toxicity as described in the protocol that is not related to disease progression, intercurrent illness or concomitant medications and that, despite optimal therapeutic intervention, meets protocol-defined criteria.

    Time frame: Within the first 28 day cycle.

  2. Phase Ib: 2. The number of participants with treatment-related adverse events.

    Data will include clinical observations, ECG parameters, clinical chemistry and haematology and vital signs assessed as the number of participants with treatment-related adverse events.

    Time frame: From baseline up to approximately 36 months.

  3. Phase Ib: 3. The number of participants with treatment-related serious adverse events.

    Data will include clinical observations, ECG parameters, clinical chemistry and haematology and vital signs assessed as the number of participants with treatment-related adverse events.

    Time frame: From baseline up to approximately 36 months.

  4. Phase III: 1. Progression Free Survival (PFS).

    Progression Free Survival (PFS) is defined as time from randomization until progression per RECIST v1.1. as assessed by BICR or death due to any cause in the overall population, the altered population, and the confirmed non-altered population. RECIST related endpoints such as PFS, ORR, DoR, CBR will be collected.

    Time frame: Up to approximately 47 months.

Secondary outcomes

  1. Phase Ib: 1. PK parameters for Palbociclib, Ribociclib, Abemaciclib: Cmax.

    Maximum observed plasma (peak) drug concentration.

    Time frame: Cycle 0 (Cycle 0 is 3 days), Cycle 1 Day 11 and Cycle 1 Day 14 (Cycle 1 is 28 days).

  2. Phase Ib: 2. PK parameters for Palbociclib, Ribociclib, Abemaciclib: AUC0-72h.

    Partial area under the plasma concentration-time curve from zero to 72 hours post-dose.

    Time frame: Cycle 0 (Cycle 0 is 3 days).

  3. Phase Ib: 3. PK parameters for Palbociclib, Ribociclib, Abemaciclib: AUC0-24h.

    Partial area under the plasma concentration-time curve from zero to 24 hours post-dose.

    Time frame: Cycle 0 (Cycle 0 is 3 days), Cycle 1 Day 11 and Cycle 1 Day 14 (Cycle 1 is 28 days).

  4. Phase Ib: 4. PK parameters for Palbociclib, Ribociclib, Abemaciclib: Cmin.

    Minimum observed plasma drug concentration.

    Time frame: Cycle 1 Day 11 and Cycle 1 Day 14 (Cycle 0 is 3 days and Cycle 1 is 28 days).

  5. Phase Ib: 5. PK parameters for capivasertib: Cmax.

    Maximum observed plasma (peak) drug concentration.

    Time frame: Cycle 1 Day 11 (Cycle 0 is 3 days and Cycle 1 is 28 days).

  6. Phase Ib: 6. PK parameters for capivasertib: AUC0-12h.

    Partial area under the plasma concentration-time curve from zero to 12 hours post-dose.

    Time frame: Cycle 1 Day 11 (Cycle 0 is 3 days and Cycle 1 is 28 days).

  7. Phase Ib: 7. PK parameters for capivasertib: Cmin.

    Minimum observed plasma drug concentration.

    Time frame: Cycle 1 Day 11 (Cycle 0 is 3 days and Cycle 1 is 28 days).

  8. Phase Ib: 8. Objective Response Rate (ORR).

    Objective Response Rate (ORR) is defined as the proportion of patients with measurable disease at baseline who have a confirmed complete response (CR) or confirmed partial response (PR), as determined by the investigator at local site per Response Evaluation Criteria in Solid Tumors (RECIST v1.1).

    Time frame: Up to approximately 36 months.

  9. Phase Ib: 9. Clinical Benefit Rate (CBR) at 24 weeks.

    Clinical Benefit Rate (CBR) 24 weeks is defined as the percentage of patients who have a CR or PR or who have SD per RECIST v1.1 as assessed by the investigator at local site for at least 23 weeks after date of first dose.

    Time frame: Up to approximately 36 months.

  10. Phase Ib: 10. Duration of Response (DoR).

    Duration of Response (DoR) will be defined as the time from the date of first documented confirmed response until date of documented progression per RECIST v1.1 as assessed by the investigator at local site or death due to any cause.

    Time frame: Up to approximately 36 months.

  11. Phase Ib: 11. Progression Free Survival (PFS).

    Progression Free Survival (PFS) is defined as time from date of first dose until progression per RECIST v1.1. as assessed by the investigator at local site or death due to any cause.

    Time frame: Up to approximately 36 months.

  12. Phase III: 1. Overall Survival (OS).

    Overall survival (OS) - time from randomization until the date of death due to any cause, secondary outcome measure in participants with HR+/HER2- locally advanced or metastatic breast cancer with gene alteration in PIK3CA/AKT1/PTEN - altered population, confirmed non-altered population and overall population.

    Time frame: Up to approximately 69 months.

  13. Phase III: 2. Objective Response Rate (ORR).

    Objective Response Rate (ORR) - the proportion of patients who have a complete or partial response, as determined by BICR per RECIST v1.1 in participants with HR+/HER2- locally advanced or metastatic breast cancer with gene alteration in PIK3CA/AKT1/PTEN - altered population, confirmed non-altered population and overall population.

    Time frame: Up to approximately 47 months.

  14. Phase III: 3. Progression Free Survival 2 (PFS2)

    Progression Free Survival 2 (PFS2) - time from randomization to the earliest of the progression event, after first subsequent therapy or death.

    Time frame: Up to approximately 69 months.

  15. Phase III: 4. Duration of Response (DoR).

    Duration of Response (DoR) - the time from the date of first documented response until the date of progression per RECIST v1.1 as assessed by BICR, or death due to any cause.

    Time frame: Up to approximately 47 months.

  16. Phase III: 5. Clinical Benefit Rate (CBR) at 24 weeks.

    Clinical Benefit Rate (CBR) at 24 weeks-the % of patients who have a CR or PR or who have SD per RECIST v1.1 as assessed by BICR for at least 23 weeks after randomisation.

    Time frame: Up to approximately 47 months.

  17. Phase III: 6. Participant-reported physical functioning

    TTD of physical functioning as measured by the physical functioning subscale of the EORTC QLQ-C30.

    Time frame: Up to approximately 69 months.

  18. Phase III: 7. Participant-reported GHS/QoL in participants

    TTD of GHS/QoL as measured by the GHS/QoL subscale of the EORTC QLQ-C30.

    Time frame: Up to approximately 69 months.

  19. Phase III: 8. Participant-reported overall side effect bother in participants in the capivasertib arm relative to control arm

    Proportion of participants experiencing different levels of overall treatment tolerability as measured by the Patient Global Impression-Treatment Tolerability (PGI-TT).

    Time frame: Up to approximately 69 months.

  20. Phase III: 9. Plasma concentration of capivasertib pre- and post-dose.

    Plasma concentration of capivasertib pre-, and post-dose.

    Time frame: Up to approximately 69 months.

  21. Phase III: 10. The number of participants with adverse events.

    Data will include clinical observations, ECG parameters, clinical chemistry / haematology / glucose metabolism parameters and vital signs assessed as the number of participants with adverse events.

    Time frame: Up to approximately 69 months.

  22. Phase III: 11. The number of participants with serious adverse events.

    Data will include clinical observations, ECG parameters, clinical chemistry / haematology / glucose metabolism parameters and vital signs assessed as the number of participants with serious adverse events.

    Time frame: Up to approximately 69 months.

07

Study locations

225 sites
  • Research Site
    Tucson, Arizona 85719, United States
  • Research Site
    Fountain Valley, California 92708, United States
  • Research Site
    Glendale, California 91204, United States
  • Research Site
    Los Angeles, California 90033, United States
  • Research Site
    Napa, California 94558, United States
  • Research Site
    San Francisco, California 94158, United States
  • Research Site
    Santa Rosa, California 92805, United States
  • Research Site
    Aurora, Colorado 80045, United States
  • Research Site
    New Haven, Connecticut 06510, United States
  • Research Site
    Newark, Delaware 19713, United States
  • Research Site
    Louisville, Kentucky 40202, United States
  • Research Site
    Annapolis, Maryland 21401, United States
  • Research Site
    Boston, Massachusetts 02215, United States
  • Research Site
    Detroit, Michigan 48236, United States
  • Research Site
    Grand Rapids, Michigan 49503, United States
  • Research Site
    Hannibal, Missouri 63401, United States
  • Research Site
    St Louis, Missouri 63110, United States
  • Research Site
    Omaha, Nebraska 68130, United States
  • Research Site
    Camden, New Jersey 08103, United States
  • Research Site
    Mineola, New York 11501, United States
  • Research Site
    New York, New York 10016, United States
  • Research Site
    New York, New York 10065, United States
  • Research Site
    Gresham, Oregon 97030, United States
  • Research Site
    Philadelphia, Pennsylvania 19104, United States
  • Research Site
    Pittsburgh, Pennsylvania 15213, United States
  • Research Site
    York, Pennsylvania 17403, United States
  • Research Site
    Greenville, South Carolina 29607, United States
  • Research Site
    Chattanooga, Tennessee 37404, United States
  • Research Site
    Nashville, Tennessee 37203, United States
  • Research Site
    Dallas, Texas 75246, United States
  • Research Site
    Houston, Texas 77030, United States
  • Research Site
    Irving, Texas 75063, United States
  • Research Site
    San Antonio, Texas 78229, United States
  • Research Site
    San Antonio, Texas 78240, United States
  • Research Site
    Salt Lake City, Utah 84106, United States
  • Research Site
    Fairfax, Virginia 22031, United States
  • Research Site
    Falls Church, Virginia 22042, United States
  • Research Site
    Midlothian, Virginia 23114, United States
  • Research Site
    Norfolk, Virginia 23502, United States
  • Research Site
    Tacoma, Washington 98405, United States
  • Research Site
    Buenos Aires, 1439, Argentina
  • Research Site
    CABA, 1414, Argentina
  • Research Site
    CABA, 1425, Argentina
  • Research Site
    CABA, C1113AAE, Argentina
  • Research Site
    CABA, C1425, Argentina
  • Research Site
    Chivilcoy, B6620LUD, Argentina
  • Research Site
    Rosario, 2000, Argentina
  • Research Site
    Darlinghurst, 2010, Australia
  • Research Site
    Nedlands, 6009, Australia
  • Research Site
    Waratah, 2298, Australia
  • Research Site
    Brasschaat, 2930, Belgium
  • Research Site
    Brussels, 1200, Belgium
  • Research Site
    Edegem, 2650, Belgium
  • Research Site
    Haine-Saint-Paul, 7100, Belgium
  • Research Site
    Leuven, 3000, Belgium
  • Research Site
    Alfenas, 37130-000, Brazil
  • Research Site
    Blumenau, 89010-340, Brazil
  • Research Site
    Natal, 59075-740, Brazil
  • Research Site
    Porto Alegre, 90035-903, Brazil
  • Research Site
    Porto Velho, 76834-899, Brazil
  • Research Site
    São Paulo, 04014-002, Brazil
  • Research Site
    Taubaté, 12030-200, Brazil
  • Research Site
    Teresina, 64049-200, Brazil
  • Research Site
    Vitória, 29043-260, Brazil
  • Research Site
    Abbotsford British Columbia, British Columbia V2S0C2, Canada
  • Research Site
    Kelowna, British Columbia V1Y 5L3, Canada
  • Research Site
    Halifax, Nova Scotia B3H 1V7, Canada
  • Research Site
    Brampton, Ontario L6R 3J7, Canada
  • Research Site
    Ottawa, Ontario K1H 8L6, Canada
  • Research Site
    Toronto, Ontario M5B 1W8, Canada
  • Research Site
    Sherbrooke, Quebec J1H 5N4, Canada
  • Research Site
    Chicoutimi, G7H 5H6, Canada
  • Research Site
    Montreal, H3T 1E2, Canada
  • Research Site
    Beijing, 100039, China
  • Research Site
    Beijing, 100044, China
  • Research Site
    Beijing, 100191, China
  • Research Site
    Beijing, 100210, China
  • Research Site
    Bengbu, 233004, China
  • Research Site
    Changchun, 130000, China
  • Research Site
    Changsha, 410013, China
  • Research Site
    Chengdu, 610041, China
  • Research Site
    Chongqing, 400042, China
  • Research Site
    Guangzhou, 510060, China
  • Research Site
    Guangzhou, 510062, China
  • Research Site
    Hangzhou, 31000, China
  • Research Site
    Hangzhou, 310022, China
  • Research Site
    Hefei, 230031, China
  • Research Site
    Nanchang, 330006, China
  • Research Site
    Nanchang, 330009, China
  • Research Site
    Nanjing, 210029, China
  • Research Site
    Nanning, 530021, China
  • Research Site
    Shandong, China
  • Research Site
    Shanghai, 200032, China
  • Research Site
    Shenyang, 110001, China
  • Research Site
    Shenyang, 110016, China
  • Research Site
    Ürümqi, 830000, China
  • Research Site
    Wuhan, 430060, China
  • Research Site
    Xi'an, 710061, China
  • Research Site
    Xuzhou, 221009, China
  • Research Site
    Zhengzhou, 450008, China

Showing the first 100 of 225 sites across 23 countries. Choose a country and city above to see the rest.

08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.

Supporting information: Study protocol, Statistical analysis plan

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure

Access criteria: When a request has been approved AstraZeneca will provide access to the deidentified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure

Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2021 (actual). Primary completion is estimated for Nov 2027, 77 months after the start.

Of 272 industry-sponsored phase 3 interventional studies under Breast Neoplasms, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 63. This study's planned 77 months is above that.

Counting every sponsor, half of 600 studies reached it within 59 months; a quarter within 36 and three quarters within 96.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 17, 2021
First posted
Apr 28, 2021
StartActual
May 10, 2021
Primary completionEst.
Nov 1, 2027
CompletionEst.
Aug 14, 2029
Last update
Aug 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 17, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04862663
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Apr 28, 2021
Start date
May 10, 2021
Primary completion
Nov 1, 2027 (estimated)
Completion
Aug 14, 2029 (estimated)
Last update
Aug 17, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Capivasertib

Start the discussion